Rogers Corp. Dl 1 Stock
Rogers Corp. Dl 1 Stock
Heavy losses for Rogers Corp. Dl 1 today as the stock fell by -€5.000 (-4.760%).
Criterium "Non-cyclic/Cyclic" is seen as the biggest plus for Rogers Corp. Dl 1 stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Rogers Corp. Dl 1 in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rogers Corp. Dl 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rogers Corp. Dl 1 | -4.760% | -12.605% | -26.761% | 82.456% | 31.646% | -31.126% | -39.884% |
| Universal Display Corp. | -0.500% | -2.071% | -7.309% | -45.248% | -31.238% | -46.319% | -64.158% |
| Vishay Intertechnology Inc. | 1.950% | -25.122% | -46.863% | 77.967% | 106.632% | 3.849% | 40.699% |
| Silicon Labs Inc. | -0.530% | 0.000% | -2.094% | 58.475% | 68.468% | 41.667% | 58.475% |
News
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Key Points
- Interested in Avalyn Pharma Inc.? Here are five stocks we like better.
- Avalyn Pharma is pursuing inhaled versions of approved pulmonary fibrosis drugs to reduce side effects that
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
Roger E. Susi, CEO, President, and Chairman of IRADIMED CORPORATION (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026
Iradimed’s CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?
Roger E. Susi, Founder, CEO, President, and Chairman of Iradimed Corporation (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock over multiple transactions on May 18 and May